Skip to content
Wenlo
Sign in
← Markets

Edwards Lifesciences Corporation

Bernard J Zovighian (CEO) sells EW shares

4EWFiled Nov 9, 2026, 4:29 PM ET· Period Nov 9, 2026

AI-generated summary

CEO, Director Bernard J Zovighian exercised 23,100 derivative shares for $1,678,908 and sold 23,100 shares for $2,379,779 at an average price of $103.02. After these trades, Bernard J Zovighian directly held 98,845 shares. These transactions were made under a Rule 10b5-1 trading plan adopted on July 28, 2026.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Bernard J Zovighian · CEO, Director

Rule 10b5-1 plan · adopted Jul 28, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Nov 9, 2026M · exercise or conversion of a derivativeFootnotes F1+23,100$72.68$1,678,908.00121,945Direct
Nov 9, 2026S · open-market saleFootnotes F1, F2−9,184$103.39$949,488.76112,761Direct
Nov 9, 2026S · open-market saleFootnotes F1, F3−13,916$102.78$1,430,290.6598,845Direct
Nov 9, 2026M · exercise or conversion of a derivativeEmployee Stock Option (Right to Acquire)Footnotes F4−23,100$0.00$0.0023,100Direct
Footnotes
  1. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026.
  2. F2 This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  3. F3 This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  4. F4 These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

More EW filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.